Gilead Sciences v. Natco Pharma: Consent Judgment & Injunction — Idelalisib Patents
Gilead Sciences sued Natco Pharma in the District of Delaware over six patents protecting Zydelig® (idelalisib) tablets, targeting Natco's ANDA No. 216921. The parties reached a confidential Settlement and License Agreement after 333 days, resulting in a court-entered consent judgment that enjoins Natco from commercialising the generic product in the United States.
Gilead shuts down Natco's idelalisib ANDA via consent judgment
On 23 September 2022, Gilead Sciences, Inc. (together with Gilead Calistoga, LLC) filed suit in the U.S. District Court for the District of Delaware against Natco Pharma Limited, asserting infringement of six U.S. patents — RE44,599, RE44,638, 8,865,730, 9,469,643, 9,492,449, and 10,730,879 — covering Zydelig® tablets containing 100 mg or 150 mg of idelalisib. The suit was triggered by Natco's ANDA No. 216921, a generic drug application seeking FDA approval to market an idelalisib tablet product in the United States.
The recorded basis of termination is Injunction Granted; the docket order is styled as a consent judgment entered on 22 August 2023. The parties agreed to the terms of a confidential Settlement and License Agreement and jointly consented to the court entering a judgment that enjoins Natco and its affiliates from making, using, offering for sale, selling, or importing the ANDA No. 216921 product in the United States, except as otherwise provided by their Agreement. All claims and counterclaims were dismissed without prejudice, and both parties waived all appellate rights from the judgment. The court retained jurisdiction for enforcement purposes.
The case resolved in 333 days — before any trial or merits ruling — consistent with the standard Hatch-Waxman ANDA litigation dynamic in which an early resolution avoids protracted validity and infringement disputes. The specific commercial terms of the confidential Settlement and License Agreement, including any licence entry date or royalty provisions, are not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Injunction Granted in 333 days
333 days from filing to consent judgment — resolved before trial
US9492449B2 — idelalisib pharmaceutical compositions and methods
Any pharmaceutical company or ANDA applicant developing a generic idelalisib tablet product targeting the U.S. market should treat the full six-patent Gilead cluster — including US9492449B2, RE44,599, RE44,638, US8865730, US9469643, and US10730879 — as a primary FTO risk. The consent judgment here resolves only this defendant's exposure; the patents remain in force and enforceable against other parties.
Official order — verbatim text
The consent judgment order confirms that the parties resolved this matter through a confidential Settlement and License Agreement, with the court entering a binding injunction against Natco's ANDA No. 216921 product. The without-prejudice dismissal of all claims and counterclaims means no merits determination was made on validity or infringement of any of the six asserted patents. The waiver of appeal and retained court jurisdiction for enforcement make this a final, immediately operative resolution.
Consent judgment: what the agreed resolution means for both parties
A binding court judgment on agreed terms — not merely a dismissal
A consent judgment is a court-entered, judicially binding resolution on terms the parties have negotiated. Unlike a voluntary dismissal, it carries the full weight of a court order. Here, the court explicitly retained jurisdiction to enforce the judgment's terms, and both parties waived all appellate rights — making the resolution final and immediately enforceable without further litigation steps.
Court-entered, final and enforceableGilead secures an injunction blocking Natco's generic idelalisib
Gilead obtained a court-ordered injunction preventing Natco and its affiliates from commercialising ANDA No. 216921 in the United States, except as the confidential Agreement may otherwise provide. This preserves Gilead's market position for Zydelig® against this particular generic challenger. The specific terms of the confidential Settlement and License Agreement are not disclosed in the available public record.
Injunction entered; Zydelig® market protectedNatco enjoined from U.S. launch — claims dismissed without prejudice
Natco is enjoined from making, selling, or importing its ANDA product in the United States except as the parties' Agreement may allow. Crucially, all of Natco's affirmative defences and counterclaims were dismissed without prejudice — meaning Natco has not formally conceded invalidity or non-infringement. The without-prejudice dismissal leaves certain legal positions formally unresolved, though both parties have waived appeal of this judgment.
Enjoined; counterclaims dismissed w/o prejudiceHatch-Waxman consent judgments: a template for idelalisib IP strategy
For generic manufacturers targeting idelalisib, this outcome signals that Gilead's six-patent portfolio presents a significant enforcement barrier. The confidential licence structure — details undisclosed — may or may not accommodate future generic entry. Rival ANDA filers and patent challengers should monitor whether additional consent judgments on similar terms follow against other applicants, which would indicate a coordinated portfolio licensing strategy by Gilead.
Portfolio enforcement in ANDA spaceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Gilead Sciences, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Natco Pharma, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Green , Jr. | Attorney | Counsel for Natco Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Seitz Van Ogtrop & Green PA | Law Firm | Representing Natco Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the PI3K inhibitor and idelalisib patent space
Forward-looking patent and innovation intelligence derived from Gilead's idelalisib enforcement action — covering portfolio activity, filing trends, and competitive white space.
Gilead's idelalisib patent estate: how deep is the moat?
Gilead asserted six patents — including two reissue patents — in a single ANDA action, suggesting a deliberately layered portfolio strategy around idelalisib. Mapping Gilead's broader PI3K-delta filing activity reveals the density of exclusivity coverage and potential expiry cliff dates that will matter for generic entry planning and competitor R&D timing.
Gilead PI3K portfolio depthPI3K-delta inhibitor filing trends: who is active beyond Gilead?
The PI3K-delta inhibitor space has attracted filings from multiple pharmaceutical companies following idelalisib's approval. Tracking patent application activity in this class — covering novel compounds, combination therapies, and formulation innovations — identifies both competitive threats to Gilead and potential white-space opportunities for next-generation inhibitors that design around existing claims.
PI3K-delta landscape trendsNatco Pharma's U.S. patent strategy in oncology generics
As a major Indian generic manufacturer, Natco Pharma has pursued U.S. ANDA approvals across multiple oncology products. Analysing Natco's patent filings, ANDA history, and IP challenges in the oncology space provides intelligence on which branded drug portfolios Natco may target next — and how innovators should proactively structure their patent defences.
Natco oncology IP activityNext-generation PI3K inhibitor formulations: where the gaps are
Gilead's patent cluster covers idelalisib compound, composition, and method-of-use claims — but adjacent areas such as novel delivery mechanisms, combination formulations with checkpoint inhibitors, or second-generation PI3K-delta selectivity profiles may represent patentable white space. Innovators can use this case's claim map as a starting point for identifying design-around opportunities.
PI3K formulation white spaceSimilar Hatch-Waxman patent cases involving oncology small-molecule drugs
Cases in the District of Delaware involving Hatch-Waxman ANDA challenges to oncology drug patents — particularly PI3K and kinase inhibitor portfolios similar to idelalisib.
What this case signals for the idelalisib and oncology IP landscape
Gilead's swift enforcement of a six-patent portfolio in Delaware sets a clear precedent for how it defends Zydelig® against generic entry.
Six-patent ANDA suits are a strong deterrent to generic launch
By asserting six patents — including two reissue patents and composition, method, and formulation claims — Gilead created a multi-layered barrier that made litigation risk high for Natco. Generic entrants should conduct thorough FTO analysis across the full idelalisib patent cluster before filing an ANDA, not just the lead compound patent.
Consent judgment with injunction is a strong Gilead enforcement signal
The combination of a court-entered injunction, waived appeal rights, and retained court jurisdiction suggests Gilead is well-positioned to enforce quickly if any future breach occurs. Other pharmaceutical companies with ANDA-targeted portfolios may adopt this enforcement template to achieve binding, non-appealable resolutions without trial.
Gilead v Natco — key questions answered
Gilead asserted six U.S. patents: RE44,599, RE44,638, 8,865,730, 9,469,643, 9,492,449, and 10,730,879. All relate to idelalisib, the active ingredient in Zydelig® tablets (100 mg and 150 mg), targeting Natco's ANDA No. 216921.
The case was resolved by a consent judgment entered on 22 August 2023. The parties agreed to a confidential Settlement and License Agreement and jointly consented to a court order enjoining Natco from commercialising its ANDA No. 216921 product in the United States. All claims and counterclaims were dismissed without prejudice, and both parties waived appellate rights.
The injunction prohibits Natco and its affiliates from making, having made, using, offering for sale, selling, or importing the ANDA No. 216921 idelalisib product in the United States, except as otherwise provided by the parties' confidential Agreement. The specific exceptions, if any, are not disclosed in the public record.
The Settlement and License Agreement is described as confidential in the consent judgment order. The specific terms — including any licence grant, authorised entry date, or royalty provisions — are not disclosed in the available public record.
Two of the six asserted patents — RE44,599 and RE44,638 — are reissue patents, which are patents reissued after the original grant to correct errors or broaden claim scope. Their inclusion in this suit suggests Gilead may have sought broader claim coverage post-issuance. For ANDA filers and FTO analysts, reissue patents can present heightened infringement risk if their claims are wider than the original grants.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.